Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bioventus Inc. (BVS:NASDAQ), powered by AI.
Bioventus Inc. is currently trading at $13.12. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bioventus Inc. on Alpha Lenz.
Bioventus Inc.'s P/E ratio is 38.5.
“Bioventus Inc. trades at a P/E of 38.5 (premium valuation) with solid ROE of 13.7%.”
Ask for details →Bioventus Inc. operates as a medical device company focused on developing innovative medical solutions for musculoskeletal healing. Primarily, it seeks to enhance patients' quality of life through its products that aid in bone healing, pain management, and osteoarthritis care. The company's notable product categories include bone health products, joint pain products, and surgical solutions, which serve a critical role in orthopedics and sports medicine. Headquartered in Durham, North Carolina, Bioventus leverages advanced biological technologies to drive advancements in healthcare. By providing both surgical and non-surgical therapies, it plays a pivotal role in the market for enhancing patient recovery and addressing orthopedic ailments. Bioventus’ contributions are significant in clinical settings and for patients seeking less invasive alternatives to traditional treatments, marking it as a key player in the intersection of medical technology and patient care.
“Bioventus Inc. trades at a P/E of 38.5 (premium valuation) with solid ROE of 13.7%.”
Ask for details →Bioventus Inc. (ticker: BVS) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 950 employees. Market cap is $874M.
The current price is $13.12 with a P/E ratio of 38.45x and P/B of 4.75x.
ROE is 13.69% and operating margin is 9.91%. Annual revenue is $568M.